VMP1 and hepatocellular carcinoma: MiR-210 targets VMP1, leading to its downregulation (Ying et al., 2011; Liu et al., 2014; Cui et al., 2015; Yang et al., 2021), which is associated with a pro-tumorigenic effect across various cancers, including lung adenocarcinoma (Cui et al., 2015), ovarian cancer (Liu et al., 2014) and hepatocellular carcinoma (Ying et al., 2011).